MYC and cancer: Heterozygous somatic alterations of MGA, the most common of which lead to loss-of-function truncation/deletion of the MYC-like bHLH domain, occur in 5% of all cancers and are commonly seen in lung adenocarcinoma, endometrial carcinoma, and colorectal cancer [7–10].